Corpus ID: 221202879

Phase I trial of glycolitic inhibition with 2-deoxyglucose and docetaxel for patients with solid tumors

  title={Phase I trial of glycolitic inhibition with 2-deoxyglucose and docetaxel for patients with solid tumors},
  author={Luis E. Raez and Virginia K. Langmuir and Kyriakos Papadopoulus and Alejandro Daniel Ricart and Caio Max S Rocha-Lima and Joseph D. Rosenblatt and James J. Schlesselman and Alan B Colowick and Don Jung and Theodore J. Lampidis},
  journal={Cancer Research},
515 Background: The slow growing cell population of solid tumors that is associated with hypoxia presents a formidable mode of resistance to chemotherapeutic agents; however anaerobic metabolism of these tumor cells also provides a window of selectivity for glycolytic inhibitors, such as 2-deoxy-D-glucose (2DG). Thus, the combination of chemotherapy (targets rapidly dividing cells) and 2DG (selectively killing the slow growing population) is expected to be more effective than either agent alone… Expand
4 Citations
Targeting the Warburg effect in hematological malignancies: from PET to therapy
Targeting the glycolytic pathway for the treatment of hematological malignancies has sufficient rationale given the utility of 18fluoro-deoxyglucose positron emission tomography in diagnostic imaging, and further research is required in developing tumor cell specific therapeutics. Expand
Protection of normal cells and tissues during radio- and chemosensitization of tumors by 2-deoxy-D-glucose.
Current understanding on the protection of normal cells and tissues against radiation- and chemotherapeutic drug-induced damage by 2-DG that makes this glucose analog an ideal adjuvant in cancer therapy are summarized. Expand
Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.
Critical roles for novel GLUT family members are revealed and a therapeutic strategy entailing selective GLUT inhibition to specifically target aberrant glucose metabolism in cancer is highlighted. Expand
An overview on Vadimezan (DMXAA): The vascular disrupting agent
DMXAA (ASA404) or Vadimezan, a flavone‐acetic acid‐based drug, is the most promising VDAs that induces a rapid shutdown of blood flow in tumors but not in normal tissue. Expand